{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-25-000040","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.197380+00:00","generated_at":"2026-05-24T03:05:05.420986+00:00","sec_items":["1.01","3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"confidence":"high","headline":"Salarius amends merger fixing 14.1% legacy ownership; Nasdaq delisting risk from $2.5M equity shortfall","bullets":["Amendment eliminates cash-based exchange ratio adjustment; legacy Salarius stockholders retain 14.1%, Decoy holders 85.9% of combined company.","Nasdaq notified Salarius on March 26, 2025 it fails minimum $2.5M stockholders' equity for continued listing.","Company must submit a compliance plan by May 12, 2025; if accepted, Nasdaq may grant up to 180 days to regain compliance.","If plan rejected or compliance not regained, Nasdaq may delist; Salarius can request a hearing for up to 180 additional days."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-25-000040","json":"https://secwatch.observer/filing/0001615219-25-000040.json","markdown":"https://secwatch.observer/filing/0001615219-25-000040.md","text":"https://secwatch.observer/filing/0001615219-25-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000040/0001615219-25-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000040/flks-20250326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:05:05.420986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}